Reviewing Gamida Cell (GMDA) and The Competition

Share on StockTwits

Gamida Cell (NASDAQ: GMDA) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Gamida Cell to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Gamida Cell and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 813 2715 5973 252 2.58

Gamida Cell currently has a consensus target price of $19.40, indicating a potential upside of 62.42%. As a group, “Biological products, except diagnostic” companies have a potential upside of 37.21%. Given Gamida Cell’s stronger consensus rating and higher probable upside, analysts clearly believe Gamida Cell is more favorable than its rivals.

Valuation & Earnings

This table compares Gamida Cell and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -1.13
Gamida Cell Competitors $934.76 million $204.36 million -1.15

Gamida Cell’s rivals have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

1.7% of Gamida Cell shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -5,041.13% -62.99% -26.24%

Summary

Gamida Cell beats its rivals on 7 of the 12 factors compared.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Weiss Asset Management LP Reduces Position in Just Energy Group Inc
Weiss Asset Management LP Reduces Position in Just Energy Group Inc
Front Row Advisors LLC Has $1.22 Million Stake in Align Technology, Inc.
Front Row Advisors LLC Has $1.22 Million Stake in Align Technology, Inc.
Front Row Advisors LLC Buys 1,000 Shares of iBonds Dec 2020 Term Corporate ETF
Front Row Advisors LLC Buys 1,000 Shares of iBonds Dec 2020 Term Corporate ETF
First Republic Bank  Shares Sold by Hahn Capital Management LLC
First Republic Bank Shares Sold by Hahn Capital Management LLC
MetLife Investment Advisors LLC Has $60.42 Million Position in Mastercard Inc
MetLife Investment Advisors LLC Has $60.42 Million Position in Mastercard Inc
Northfield Bancorp Inc  EVP Robin Lefkowitz Sells 769 Shares
Northfield Bancorp Inc EVP Robin Lefkowitz Sells 769 Shares


© 2006-2019 Ticker Report